Intranasal mupirocin for outbreaks of methicillinresistant Staphylococcus aureus

American Journal of Health-System Pharmacy

Volumn 54, Issue 19, 1997, Pages 2185-2191

  Bertino Jr , Joseph S ^a,b  

^a Clin Pharmacology Research Center   (United States)

^b BASSETT HEALTHCARE   (United States)

Author keywords

Antibiotics; Clinical studies; Control; Cross infection; Dosage; Drug administration routes; Methicillin; Mupirocin calcium; Nasal preparations; Ointments; Penicillins; Resistance; Staphylococcal infections; Staphylococcus aureus; Topical preparations; Toxicity

Indexed keywords

PSEUDOMONIC ACID;

BACTERIAL COLONIZATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; EPIDEMIC; ERYTHEMA; HEALTH CARE PERSONNEL; HUMAN; INFECTION CONTROL; INTRANASAL DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NOSE SMEAR; OINTMENT; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PRURITUS; PSEUDOMONAS FLUORESCENS; RESPIRATORY TRACT DISEASE; REVIEW; STAPHYLOCOCCUS INFECTION; TOPICAL DRUG ADMINISTRATION;

EID: 0030867795     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.19.2185     Document Type: Review

References (45)

1. Barrett FF, McGehee RF Jr, Finland M. Methicillin-resistant Staphylococcus aureus at Boston City Hospital: bacteriologic and epidemiologic observations. N Engl J Med. 1968; 279:441-8.
2. Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med. 1996; 124:329-34.
3. Boyce JM. Methicillin-resistant Staphylococcus aureus in hospitals and long-term care facilities: microbiology, epidemiology, and preventive measures. Infect Control Hosp Epidemiol. 1992; 13:725-37.
4. Boyce JM. Methicillin-resistant Staphylococcus aureus: a continuing infection control challenge. Eur J Clin Microbiol Infect Dis. 1994; 13(1):45-9. Editorial.
5. Goldmann DA, Weinstein RA, Wenzel RP et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA. 1996; 275:234-40.
6. Wenzel RP, Nettleman MD, Jones RN et al. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am J Med. 1991; 91(suppl 3B): 221S-7S.
7. Fekety FR Jr. The epidemiology and prevention of staphylococcal infection. Medicine. 1964; 45:593-613.
8. Casewell MW, Hill RLR. Elimination of nasal carriage of Staphylococcus aureus with mupirocin ('pseudomonic acid') - a controlled trial. J Antimicrob Chemother. 1986; 17:365-72.
9. Fernandez C, Gaspar C, Torrellas A et al. A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother. 1995; 35:399-408.
10. Reagan DR, Doebbeling BN, Pfaller MA et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med. 1991; 114:101-6.
11. Mulligan ME, Murray-Leisure KA, Ribner BS et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med. 1993; 94:313-28.
12. Wenzel RP, Reagan DR, Bertino JS et al. Methicillin-resistant Staphylococcus aureus outbreak: a consensus panel's definition and management guidelines. Am J Infect Control. In press.
13. Guzzo CA, Lazarus GS, Werth VP. Dermatological pharmacology. In: Hardman JG, Limbird LE, Molinoff PB et al., eds. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:1593-616.
14. Slocombe B, Perry C. The antimicrobial activity of mupirocin - an update on resistance. J Hosp Infect. 1991; 19(suppl B):19-25.
15. Sutherland R, Boon RJ, Griffin KE et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985; 27:495-8.
16. Hill RLR, Casewell MW. Stability of mupirocin in organic substances with particular reference to treating nasal carriage of methicillin-resistant Staphylococcus aureus. Proceedings of the 7th International Symposium on Future Trends in Chemotherapy. 1986; 147. Abstract.
17. Hudson IRB. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. J Hosp Infect. 1994; 27:81-98.
18. Coello R, Jiménez J, García M et al. Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 990 patients. Eur J Clin Microbiol Infect Dis. 1994; 13(1):74-81.
19. Kauffman CA, Terpenning MS, He X et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am J Med. 1993; 94:371-8.
20. Terpenning MS, Bradley SF, Wan JY et al. Colonization and infections with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc. 1994; 42:1062-9.
21. Hill RLR, Casewell MW. Nasal carriage of MRSA: the role of mupirocin and outlook for resistance. Drugs Exp Clin Res. 1990; 16:397-402.
22. Kaye ET, Kaye KM. Topical antibacterial agents. Infect Dis Clin North Am. 1995; 9:547-59.
23. Cookson BD, Lacey RW, Noble WC et al. Mupirocin-resistant Staphylococcus aureus. Lancet. 1990; 335:1095-6.
24. Smith GE, Kennedy CTC. Staphylococcus aureus resistant to mupirocin. J Antimicrob Chemother. 1988; 21:141-2. Letter.
25. Layton MC, Perez M, Heald P et al. An outbreak of mupirocin-resistant Staphylococcus aureus on a dermatology ward associated with an environmental reservoir. Infect Control Hosp Epidemiol. 1993; 14:369-75.
26. Casewell MW, Hill RLR. In vitro activity of mupirocin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1985; 15:523-31.
27. Bactroban Nasal package insert. Philadelphia, PA: SmithKline Beecham Pharmaceuticals; 1995 Nov.
28. Dacre JE, Emmerson AM, Jenner EA. Nasal carriage of gentamicin and methicillin resistant Staphylococcus aureus treated with topical pseudomonic acid. Lancet. 1983; 2:1036. Letter.
29. Doebbeling BN, Breneman DL, Neu HC et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. Clin Infect Dis. 1993; 17:466-74.
30. Scully BE, Briones F, Gu J et al. Mupirocin treatment of nasal staphylococcal colonization. Arch Intern Med. 1992; 152:353-6.
31. McAnally TP, Lewis MR, Brown DR. Effect of rifampin and bacitracin on nasal carriers of Staphylococcus aureus. Antimicrob Agents Chemother. 1984; 25:422-6.
32. Wheat LJ, Kohler RB, White AL et al. Effect of rifampin on nasal carriers of coagulase-positive staphylococci. J Infect Dis. 1981; 144:177.
33. Cederna JE, Terpenning MS, Ensberg M et al. Staphylococcus aureus nasal colonization in a nursing home: eradication with mupirocin. Infect Control Hosp Epidemiol. 1990; 11:13-6.
34. Coello R, Fernández C, Arroyo P et al. Success and failure in the control of methicillin-resistant Staphylococcus aureus. In: Coello R, Casewell MW, eds. Methicillin-resistant Staphylococcus aureus. International clinical practice series. Spain: 1992 Mar:95-8.
35. Dacre J, Emmerson AM, Jenner EA. Gentamicin methicillin-resistant Staphylococcus aureus: epidemiology and containment of an outbreak. J Hosp Infect. 1986; 7:130-6.
36. Davies EA, Emmerson AM, Hogg GM et al. An outbreak of infection with a methicillin-resistant Staphylococcus aureus in a special care baby unit: value of topical mupirocin and of traditional methods of infection control. J Hosp Infect. 1987; 10:120-8.
37. Duckworth GJ, Lothian JLE, Williams JD. Methicillin-resistant Staphylococcus aureus: report of an outbreak in a London teaching hospital. J Hosp Infect. 1988; 11:1-15.
38. Parras F, Guerrero MC, Bouza E et al. Comparative study of mupirocin and oral cotrimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1995; 39:175-9.
39. Boelaert JR, De Smedt RA, De Baere YA et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant. 1989; 4:278-81.
40. Boelaert JR, De Baere Y, Godard C et al. Eradication of Staphylococcus aureus in dialysis by nasal mupirocin. Paper presented at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, TX; 1989 Sep 20.
41. Boelaert JR, Van Landuyt HW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteremias in haemodialysis patients. Nephrol Dial Transplant. 1993; 8:235-9.
42. Hingst V, Vergetis W, Bommer J et al. Prospective randomised placebo-controlled study concerning the elimination of Staphylococcus aureus by means of mupirocin in patients undergoing hemodialysis. Proceedings of the International Congress on Management of Infection. 1992 Apr 5-9:2. Abstract 110.
43. Holton DL, Nicolle LE, Diley D et al. Efficacy of mupirocin nasal ointment in eradicating Staphylococcus aureus nasal carriage in chronic haemodialysis patients. J Hosp Infect. 1991; 17:133-7.
44. Watanakunakorn C, Brandt J, Durkin P et al. The efficacy of mupirocin ointment and chlorhexidine body scrubs in the eradication of nasal carriage of Staphylococcus aureus among patients undergoing long-term hemodialysis. Am J Infect Control. 1992; 20:138-41.
45. Red Book Update. 1997; 16(3):20.